FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
October 1, 2015
Campaign to coincide with new HeartCheck™ ECG PEN advertising Initiatives
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today announced the signing of a 12 month investor awareness program agreement with Stockhouse Publishing Ltd. ("Stockhouse") of Vancouver, Canada.
With this agreement CardioComm Solutions will begin a set of structured campaigns to expand customer and investor awareness of its consumer and hospital biotechnology, health & wellness and heart monitoring innovations across a broader investor cross-section. The Company's flagship products are the HeartCheck™ ECG PEN and its hospital based Global ECG Management Solutions for Windows (GEMS™ WIN). This campaign also coincides with the launch of the Company's new HeartCheck™ website (www.theheartcheck.com) that has a focus on consumer and pharmacist based education, sales and marketing.
Looking ahead to the next two fiscal quarters where a number of pending deals are expected be completed, CardioComm Solution is seeking to leverage Stockhouse's 18 years of experience and over 1 million readers that visit the Stockhouse website each month, of which 25% are accredited investors. The Stockhouse support will involve a variety of products and services that will generate new content designed to increase communication exposure, develop a wider audience following and the development of credible content that is of interest to the investment community.
Stockhouse confirmed that the relationship with CardioComm Solutions is both timely and relevant and fits well within Stockhouse's objective to bring their readership a clear and fact-based profile of uniquely positioned companies in the healthcare and wellness market. The CardioComm Solutions-Stockhouse engagement, valued at $62,304, can be extended at the discretion of the Company and will involve third party analyst coverage, research and insight from industry experts at a time where there is a trend of investors seeking health-based technology companies for investment opportunities versus resource-based companies.
To learn more about CardioComm Solutions' consumer HeartCheck™ ECG products and their hospital-based ambulatory cardiac arrhythmia technologies GEMS™ WIN, please see the Company's websites at www.theheartcheck.com and www.cardiocommsolutions.com
About Stockhouse Publishing
Stockhouse Publishing Ltd. is a leading financial media company that serves financial institutions, media publishers, public companies and brand advertisers. Stockhouse Publishing helps individual investors create and manage their personal wealth by delivering an unparalled array of aggregated news and information, portfolio management and analysis tools, and a forum for capturing and accessing user-generated content. Stockhouse is Canada's #1 financial portal and one of North America's largest small cap investor communities and Stockhouse.com serves as a global hub for investors to find relevant financial news, access expert analysis and opinion and share knowledge and information with each other.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.